专注于眼科药物领域的沈阳兴齐眼药（300573）股份有限公司(以下简称"兴齐眼药")拟通过定增融资进 一步加码研发创新，提升企业的发展动能。据兴齐眼药5月27日晚间披露的定增预案，公司拟通过向特 定对象发行股票的方式募集资金不超过8.5亿元，其中6.5亿元用于研发中心建设项目，2亿元用于补充流 动资金。 "研发中心项目有助于加强技术研发和创新能力，提高公司的核心竞争力。补充流动资金有助于应对市 场变化和竞争压力，增强公司的抗风险能力。"澳大利亚资深注册会计师谢宗博向《证券日报》记者表 示，如果募投项目最终都能顺利实施，将有助于推动兴齐眼药的业务增长和可持续发展。 经营业绩持续高增长 据公告，兴齐眼药此次募投的研发中心建设项目旨在构建眼科领域标杆案例，打造集智能实验室矩阵、 跨国研发协作中枢、产学研协同创新平台为一体的研发中心，搭建精准制剂技术、多维药理评价、整合 式药代评价、药物包材研究等平台。该项目将搭建智慧化管理系统，可加速药物研发成果转化与上市进 程，构建集智能化、精准化、高效化于一体的国际一流眼科研发基地。 全面提升研发实力 兴齐眼药是一家主要从事眼科药物研发、生产、销售的高新技术企业。公司于2016 ...

Core Viewpoint - The company plans to issue shares to specific investors in 2025, raising up to 850 million yuan, which may dilute immediate returns for existing shareholders [2][3][8]. Group 1: Financial Impact of Share Issuance - The total number of shares before the issuance is 245,348,945, and the maximum number of shares to be issued is 73,604,683, which represents up to 30% of the pre-issuance total [2][3][6]. - The projected net profit for 2025, assuming no growth, is estimated to remain at 347,542,460 yuan, leading to a basic earnings per share (EPS) of 1.38 yuan post-issuance [6][7]. - Under three scenarios of net profit growth (0%, 10%, and 20%), the diluted EPS and return on equity (ROE) will decrease post-issuance, indicating a potential dilution of shareholder returns [6][7][8]. Group 2: Necessity and Reasonableness of the Issuance - The funds raised will be allocated to the construction of a research and development center and to supplement working capital, aligning with the company's strategic direction and industry trends [9][10]. - The issuance is deemed necessary to enhance the company's R&D capabilities and improve its financial structure, which is expected to strengthen its competitive position in the market [9][10][11]. Group 3: Measures to Mitigate Dilution of Returns - The company plans to implement measures to counteract the dilution of immediate returns, including enhancing core business operations and improving fund management [9][11]. - Commitments from major stakeholders, including the controlling shareholder and management, have been made to ensure the effectiveness of these measures and to protect shareholder interests [12][13].

Fundraising Plan - The company plans to raise a total of no more than 850 million yuan, with the net amount after deducting issuance costs to be used entirely for project construction [1] - The total investment for the projects exceeds the net amount raised, with the company planning to cover the shortfall through self-funding or other financing methods [1] Necessity and Feasibility of Fundraising - The R&D center construction project is a continuation of a previous fundraising initiative, aimed at addressing a funding gap to ensure smooth project development [2][3] - The project aims to establish a comprehensive R&D headquarters with international vision, focusing on intelligent, digital, and international research capabilities [2] Project Details - The total investment for the R&D center is 984.23 million yuan, with 207.97 million yuan already invested from previous fundraising efforts and 650 million yuan planned from the current fundraising [3][4] - The project will include advanced facilities such as a high-standard data center and automated systems to enhance research efficiency and data reliability [3] R&D Focus and Market Position - The company emphasizes the importance of R&D as a core driver for pharmaceutical development, with a focus on building a strong pipeline of innovative products [5][6] - Recent product launches, including a treatment for dry eye syndrome, have significantly contributed to revenue growth, with total revenue increasing from approximately 689 million yuan in 2020 to about 1.943 billion yuan in 2024 [5][6] Future R&D Directions - The company is expanding its product line in the ophthalmology sector, focusing on innovative treatments for various eye diseases, including age-related macular degeneration and diabetic macular edema [7][8] - The development of new treatment methods, including gene therapy, is seen as a key opportunity for the company to enhance its market position [7] Financial Impact of Fundraising - The fundraising will improve the company's liquidity and capital structure, enhancing its ability to manage risks and support sustainable growth [12][13] - The successful implementation of the fundraising projects is expected to strengthen the company's core competitiveness and long-term viability [13]

Core Viewpoint - The report provides a detailed account of the fundraising activities and the utilization of the raised funds by Shenyang Xingqi Eye Pharmaceutical Co., Ltd. as of December 31, 2024, highlighting the financial figures and project statuses [1][2][3]. Fundraising Overview - The company raised a total of RMB 599,669,492.10 through the issuance of 5,763,282 shares, with actual funds received amounting to RMB 581,870,425.73 after deducting underwriting fees [1][2]. - The funds were fully received by December 22, 2021, and verified by a certified public accountant [1]. Fund Utilization - As of December 31, 2024, the total amount of funds utilized was RMB 382,520,531.09, with remaining funds of RMB 195,077,792.24 held in a dedicated bank account [2][3]. - The company has not changed the investment projects but adjusted the implementation locations for certain projects, specifically the "R&D Center Construction" project [2][3]. Project Status and Economic Benefits - The "Single-Dose Production Line Construction" project is expected to achieve an internal rate of return of 51.96% and a net present value of RMB 904,582,400, with an anticipated annual revenue of RMB 1,970,283,200 once operational [4]. - The "R&D Center Construction and New Drug Development" project aims to enhance the company's R&D capabilities, although direct economic benefits cannot be quantified at this stage due to the nature of drug development processes [4]. Financial Summary - The total amount of funds raised was RMB 599,669,492.10, with cumulative usage amounting to RMB 399,868,000, indicating a significant portion of the funds has been allocated to various projects [3][4]. - The company has approved the permanent allocation of surplus funds to supplement working capital, reflecting a strategic financial management approach [2][3].

Meeting Announcement - The company will hold its first extraordinary general meeting of shareholders in 2025 on June 13, 2025, at 14:30 [1] - The meeting will be conducted both in-person and via online voting [2] Voting Procedures - Shareholders can vote in person or authorize a representative to attend the meeting [2] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system from 9:15 to 15:00 on June 13, 2025 [2][5] Agenda Items - The meeting will discuss several proposals, including the plan for issuing A-shares to specific targets for the year 2025 [3][4] - All proposals require a two-thirds majority approval from attending shareholders [4] Registration Details - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [4][5] - Registration can also be done via mail, fax, or email for remote shareholders [4][5] Contact Information - The company has provided contact details for inquiries related to the meeting [5]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-021 沈阳兴齐眼药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 过电子邮件等形式送达至各位董事，董事会会议通知中包括会议的相关资料，同 时列明了会议的召开时间、地点、内容和方式。 的方式召开。 本次董事会。 二、董事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于公司符合向特定对象发行 A 股股票条件的议案》 根据《中华人民共和国公司法》 《中华人民共和国证券法》 《上市公司证券发 行注册管理办法》等有关法律法规的规定，对照上市公司向特定对象发行股票的 条件，董事会对公司的实际情况及相关事项进行认真的自查论证后，认为公司符 合向特定对象发行 A 股股票的资格和条件，同意公司申请本次向特定对象发行人 民币普通股（A 股）股票（以下简称"本次发行"）。 表决结果：9 票赞成，0 票反对，0 票弃权。 本议案已经公司董事会审计委员会、独立董事专门会议审议通过。尚需提交 股东大会审议。 律法规和《公司章程》的有关规定。 （二）审议通过《关于公司 2 ...

一、审议通过《关于公司符合向特定对象发行A股股票条件的议案》 经审议，独立董事认为，公司符合《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司证券发行注册管理办法》等法律法规、规范性文件关于向特定对 象发行A股股票的有关规定，具备向特定对象发行A股股票的条件。 沈阳兴齐眼药股份有限公司 第五届董事会独立董事专门会议 2025 年第二次会议决议 沈阳兴齐眼药股份有限公司（以下简称"公司"）第五届董事会独立董事专门 会议 2025 年第二次会议通知于会议召开前 3 日以电子邮件的形式发出，会议于 2025 年5月27 日在公司会议室以现场与通讯会议相结合的方式召开。公司独立董事共 3 人， 出席本次会议的独立董事共 3 人，会议由独立董事徐先梅女士召集并主持。本次会 议的召开符合《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《沈阳兴齐眼药股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 会议形成的决议合法、有效。与会独立董事经认真讨论，形成如下决议： 独立董事一致同意该议案，并同意将本议案提交公司 ...

证券代码：300573 证券简称：兴齐眼药 沈阳兴齐眼药股份有限公司 SHENYANG XINGQI PHARMACEUTICAL CO., LTD. （中国（辽宁）自由贸易试验区沈阳片区新运河路 25 号） 2025 年度向特定对象发行股票 方案论证分析报告 二〇二五年五月 | 目 录 1 | | | --- | --- | | 释 2 | 义 | | 一、本次发行的背景和目的 4 | | | （一）本次发行的背景 4 | | | （二）本次发行的目的 5 | | | 二、本次发行证券及其品种选择的必要性 6 | | | （一）本次发行证券的品种 6 | | | （二）本次发行证券品种选择的必要性 6 | | | 三、本次发行对象的选择范围、数量和标准的适当性 7 | | | （一）本次发行对象选择范围的适当性 7 | | | （二）本次发行对象数量的适当性 7 | | | （三）本次发行对象标准的适当性 8 | | | 四、本次发行定价的原则、依据、方法和程序的合理性 8 | | | （一）本次发行定价的原则和依据 8 | | | （二）本次发行定价的方法和程序 9 | | | 五、本次发行方式的可行性 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-023 沈阳兴齐眼药股份有限公司 关于 2025 年度向特定对象发行股票 预案披露的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2025 年 5 月 27 日召开 了第五届董事会第九次会议和第五届监事会第九次会议，审议通过了《关于公司 2025 年度向特定对象发行股票预案的议案》。《沈阳兴齐眼药股份有限公司 2025 年度向特定对象发行股票预案》及相关文件于中国证监会指定的创业板信息披露 网站巨潮资讯网（http://www.cninfo.com.cn）上披露，敬请投资者注意查询。 公司2025年度向特定对象发行股票预案的披露事项不代表审批机关对本次 发行股票相关事项的实质性判断、确认或批准。本预案所述本次向特定对象发行 股票相关事项的生效和完成尚待公司股东大会通过、深圳证券交易所审核通过并 经中国证监会作出同意注册决定。敬请广大投资者注意投资风险。 特此公告。 沈阳兴齐眼药股份有限公司 董事会 2025 年 5 月 27 日 1 ...

证券代码：300573 证券简称：兴齐眼药 沈阳兴齐眼药股份有限公司 SHENYANG XINGQI PHARMACEUTICAL CO., LTD. （中国（辽宁）自由贸易试验区沈阳片区新运河路 25 号） 2025 年度向特定对象发行股票 预案 二〇二五年五月 沈阳兴齐眼药股份有限公司 2025年度向特定对象发行股票预案 公司声明 1、公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存 在虚假记载、误导性陈述或重大遗漏，并对本预案内容的真实性、准确性、完整 性承担个别和连带的法律责任。 2、本预案按照《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司证券发行注册管理办法》等法律法规及规范性文件的要求编制。 3、本次向特定对象发行股票完成后，公司经营与收益的变化由公司自行负 责，因本次向特定对象发行股票引致的投资风险由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行股票的说明，任何与之相反 的声明均属不实陈述。 本部分所述的词语或简称与本预案释义中所定义的词语或简称具有相同的 含义。 1、本次向特定对象发行的方案及相关事项已经 2025 年 5 月 27 日召开的公 司第五 ...